SOLIGENIX INC (SNGX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
$0.37-2.88%
Close 2026-09-09 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
Broken: Primary pillar broken — Regain Nasdaq minimum $1.00 bid price compliance: price $0.38 vs $1.00 target.
Soligenix aims to fix Nasdaq listing issues. It plans $90M revenue in 2026. The company raised $2.96M by selling shares. Ending the failed HyBryte program cuts losses.
The company lost money and faces delisting risks. Revenue is expected to fall 60%. The recent selloff shows weak confidence. Debt raises may dilute shareholders.
The market expects about 60% revenue decline. Our fair value is near $2.00. We see risk but some recovery potential.
Breaks if: capital raised falls short of $2.96 million by mid-2026
Breaks if: share price falls below $1.00 for more than 30 days
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a high-risk, speculative growth opportunity. The company is currently loss-making and has faced recent challenges, including a notice of delisting, which adds to its risk profile.
The market appears to price SNGX as relatively cheap compared to its peers, but there is a notable expectations gap. This suggests that investors may be cautious about the company's future performance given its current challenges.
Fundamentals are likely to remain under pressure due to ongoing losses and the need for capital raising. Recent management changes and the termination of the HyBryte development program indicate a strategic shift that may affect future performance.
The long-term thesis hinges on management's ability to address compliance issues and execute strategic options effectively. Additionally, the performance of sector bellwethers and the overall economic environment will be crucial in determining SNGX's trajectory.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Resolve non-compliance with Nasdaq minimum bid price requirement to maintain listing on Nasdaq Capital Market.
Newly stated in 2026-Q2. The company received a Nasdaq notice on June 10, 2026, for non-compliance with the $1.00 minimum bid price rule. No financial metrics directly quantify this priority, but the regulatory event marks a critical compliance issue. The trajectory is newly identified and requires resolution.
“Company received a written notice from Nasdaq indicating non-compliance with the $1.00 minimum bid price requirement.”
Breaks if: HyBryte program restarts or continues beyond mid-2026
Halt development of HyBryte following interim Phase 3 FLASH2 trial results showing futility and evaluate strategic options.
Newly stated in 2026-Q2. The company halted the HyBryte FLASH2 Phase 3 trial due to futility as announced in April 2026. Management disclosed approximately $5.9 million cash on hand and plans to evaluate strategic options including M&A and advancing other assets. The trajectory reflects a strategic shift away from HyBryte development.
“Data Monitoring Committee recommended halting FLASH2 trial for futility; company to evaluate all strategic options.”
Breaks if: annual revenue falls below $90 million in 2026
Overall, SNGX is in a precarious position with significant risks ahead. The next few quarters will be critical for its future direction. Not investment advice.